Moleculin Biotech, Inc. MBRX

Exactly 3G Cardio

Got my proxy material today from ML. Went to vote online and it said ‘0’ shares available to vote. I looked more carefully at the ML proxy statement and it too said 0. I checked my brokerage account and I still shows my thousands of shares correctly. Anyone else having this issue with ML?

Yes and the SEC now should have no problem granting any listing issues extension until illegal naked short impact has been resolved. Any r/s discussion should be tabled and energy should be focused on core trials

Ok Wally, this upcoming refried attempt of the earlier reverse stock proposal with new quorum rules you snuck in still won’t fly with me. I would suggest you use the remaining two months to the SEC checkpoint to focus on results oriented endeavors rather than smoke and mirrors because I’m beginning to think this is a management issue needing resolution rather than the science itself. I hope you quickly implement a plan b.

Too many balls in the air causing jack of all trades master of nothing—-may work out but not the way I would have done it. Better to get the prime lead trial to early pivotal to ensure a cash cow and investor confidence and your first rule of business. Now we’ve just playing games over next few months to year unnecessarily while we listen to stale re-runs. Should have had twice the trials on the lung indication even if he used the available sizable LOC until they didn’t renew and that alone raised concern as to why didn’t they?

Most significant is abstaining no longer registers as a no vote on most matters like in last proxy joke…see the greedy game to push their agenda now? If these rules were in place in last proxy vote, their dumb r/s would have passed.

When it pivots into pha 3 trial for one or more indications- that’s when ! Should already be in that position if not for this mgmt team with too many balls in the air. Not enough clinical sites in play for any one Indication especially with the now too often used cliche of no toxicity - we get I now get on with the efficacy demonstration on an expedited basis. I you’re not on the FDA’s calendar discussing pivotal plans, I have no interest in quarterly updates on trials-pretty boring and thus the sp.

Yawn yawn yawn

It worked for CNSP